Everest Medicines’ (HKEX 1952.HK, “Everest”, or the “Company”) partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)…
Author: admin
RTLS in healthcare market to grow by USD 3.2737 billion between 2022 to 2027; Growth opportunities led by Advantech Co. Ltd. and AiRISTA Flow Inc.- Technavio
The latest report on RTLS in the healthcare market, 2022-2027 estimates to register an incremental growth of USD 3,273.72 million at a CAGR…
YOUTUBE ADS FOR BEGINNERS: HOW TO ADVERTISE ON YOUTUBE
What is YouTube Advertising? YouTube advertising, done through Google Ads, is a way of advertising your…
51 Free Microsoft Word Resume Templates That’ll Land You the Job
When it comes to resumes, presentation is just as important as the skills and experience that…
How to Create an Ebook In 7 Steps (2023 Beginner’s Guide)
Whether you’re trying to create an ebook or learn how to design an ebook on your…
STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition
STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small…
Nasus Pharma anuncia la publicación de sus resultados clínicos positivos con el aerosol de epinefrina en polvo intranasal FMXIN002 en el Journal of Allergy and Clinical Immunology In Practice
Nasus Pharma Ltd una compañía biofarmacéutica de etapa clínica enfocada en desarrollar una cartera de productos intranasales…
New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services
Roche (SIX: RO, ROG; OTCQX: RHHBY) – Harvard Business Review Analytic Services (HBRAS) today unveiled its 2023 Report…
SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile (SV95C) for Duchenne Muscular Dystrophy
SYSNAV Healthcare announces that the European Medicines Agency (EMA) considers that for ambulant Duchenne Muscular Dystrophy…
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan
Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has…